Hyperkalemia is a diseases in which levels of potassium are higher than normal level (3.5 and 5.0 mmol/L) in blood serum. Kidneys are responsible for managing potassium balance in the body by regulating its excretion as well as its intake. A person is prone to develop hyperkalemia when the consumption of potassium exceeds that of kidneys’ potential to excrete it. The right amount of potassium and sodium in the body play a vital role in normal functioning of the myocardium.

Hyperkalemia can occur due to congestive heart failure, chronic kidney disease, or diabetic kidney disease. The condition can also occur when a patient receives renin-angiotensin-aldosterone system inhibitors (RAAS) in kidney disease. Abnormal levels of potassium can lead to irregular heartbeats, which can be fatal. Hyperkalemia is diagnosed by kidney functioning test, creatinine blood test, blood tests, and glucose monitoring.
This report contains market size and forecasts of Hyperkalemia Treatment in global, including the following market information:
Global Hyperkalemia Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Hyperkalemia Treatment Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Hyperkalemia Treatment companies in 2021 (%)
The global Hyperkalemia Treatment market was valued at 555.6 million in 2021 and is projected to reach US$ 1991.1 million by 2028, at a CAGR of 20.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Patiromer Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hyperkalemia Treatment include Vifor Pharma, Astrazeneca, Sanofi, CMP Pharma and Belcher Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hyperkalemia Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hyperkalemia Treatment Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Hyperkalemia Treatment Market Segment Percentages, by Type, 2021 (%)
Patiromer
Sodium Zirconium Cyclosilicate
Global Hyperkalemia Treatment Market, by Distribution Channel, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Hyperkalemia Treatment Market Segment Percentages, by Distribution Channel, 2021 (%)
Hospital Pharmacy
Retail Pharmacy
Global Hyperkalemia Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Hyperkalemia Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hyperkalemia Treatment revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Hyperkalemia Treatment revenues share in global market, 2021 (%)
Key companies Hyperkalemia Treatment sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Hyperkalemia Treatment sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Vifor Pharma
Astrazeneca
Sanofi
CMP Pharma
Belcher Pharmaceuticals